Sympathetic Activation and Arrhythmogenesis after Myocardial Infarction: Where Do We Stand?

Area of Science:

• Cardiology
• Neuroscience
• Pharmacology

Background:

• Myocardial infarction (MI) causes left ventricular remodeling and high mortality from ventricular tachyarrhythmias.
• Current treatments like beta-blockers and defibrillators are insufficient for chronic-phase arrhythmias post-MI.
• Pathophysiology involves sympathetic nerve alterations and flow-innervation mismatches, creating an arrhythmogenic environment.

Purpose of the Study:

• To review the pathophysiology of ventricular arrhythmogenesis after myocardial infarction.
• To highlight the role of sympathetic activation in post-MI heart failure and arrhythmias.
• To discuss emerging pharmacologic and non-pharmacologic neuromodulation strategies.

Main Methods:

• Review of histological and functional studies on post-MI cardiac remodeling.
• Analysis of research on autonomic dysfunction and its contribution to arrhythmias.
• Synthesis of findings from pre-clinical and clinical trials on neuromodulation therapies.

Main Results:

• Sympathetic nerve ending alterations and flow-innervation mismatches are key arrhythmogenic factors post-MI.
• Aldosterone inhibitors, sacubitril/valsartan, and SGLT2 inhibitors demonstrate antiarrhythmic effects.
• Investigational non-pharmacologic therapies include vagal stimulation, stellate ganglion modulation, and renal sympathetic denervation.

Conclusions:

• Understanding sympathetic activation is crucial for managing post-MI ventricular arrhythmias.
• Pharmacologic and non-pharmacologic neuromodulation represent promising therapeutic avenues.
• Further research is needed to optimize these strategies for improved patient outcomes.